Clinical Trials Logo

Eye Diseases clinical trials

View clinical trials related to Eye Diseases.

Filter by:

NCT ID: NCT05424549 Completed - Dry Eye Syndromes Clinical Trials

A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease

Start date: March 9, 2022
Phase: Phase 2
Study type: Interventional

A Randomized, Double-Masked, Vehicle-Controlled Crossover Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

NCT ID: NCT05411367 Completed - Dry Eye Disease Clinical Trials

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

SIDE
Start date: July 28, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of SI-614 ophthalmic solution compared with placebo in patients with dry eye

NCT ID: NCT05403827 Completed - Dry Eye Disease Clinical Trials

A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease

Start date: July 3, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of K-161 ophthalmic solution for the treatment of moderate to severe dry eye disease.

NCT ID: NCT05378945 Completed - Dry Eye Disease Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease

Start date: July 22, 2022
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline solution) Nasal Spray as compared to placebo (vehicle) on signs and symptoms of dry eye disease.

NCT ID: NCT05372107 Completed - Dry Eye Disease Clinical Trials

A Study of AG-80308 in Dry Eye Patients

Start date: June 13, 2022
Phase: Phase 1
Study type: Interventional

This is a multicenter, double-masked, randomized, parallel-group study with topical AG-80308 eye drops in dry eye patients.

NCT ID: NCT05370495 Completed - Dry Eye Disease Clinical Trials

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

Start date: July 25, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 2, multi-center, double-masked, randomized, vehicle-controlled, dose-response, parallel-group study designed to evaluate the safety and tolerability and ocular efficacy of SY-201 Ophthalmic Solution versus vehicle over a 60-day treatment period in subjects with dry eye disease (DED).

NCT ID: NCT05360966 Completed - Dry Eye Disease Clinical Trials

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

Start date: July 18, 2022
Phase: Phase 3
Study type: Interventional

This will be a Phase 3, multicenter, vehicle-controlled, double-masked, randomized study conducted at approximately 20 sites in the United States. All subjects enrolled will have dry eye disease (DED). The study will consist of Screening (Day -14) and Baseline (Day 1) visits as well as visits at Day 7, Day 14, Day 28, and Day 90 (Study Exit).

NCT ID: NCT05345119 Completed - Clinical trials for Graves Ophthalmopathy

Sirolimus in Graves' Orbitopathy

RETROSIRGO
Start date: January 15, 2020
Phase:
Study type: Observational

Graves' Orbitopathy (GO) is a disabling and disfiguring condition associated with Graves' Disease, due to autoimmunity against antigens expressed by the thyroid and orbital tissues, and resulting in orbital fibroblast proliferation and release of glycosaminoglycans. The current treatments available, especially glucocorticoids, are not effective in all patients. Two cases of patients with GO treated with Sirolimus have been reported with an excellent response to the drug. The rationale for the use of Sirolimus lies in its mechanisms of action. Sirolimus is able to inhibit T-cell activation as well as fibroblast proliferation. In addition, acts indirectly on the Insulin-Like Growth Factor-1 (IGF-1) pathway, and recent clinical trials have shown that a monoclonal antibody against the IGF-1 receptor (Teprotumumab) is effective in patients with GO. Thus, Sirolimus could be used in GO as monotherapy in patients with GO. The aim of the present drug vs standard treatment, observational study is to evaluate the efficacy of Sirolimus as a second-line treatment in patients with moderately severe, active GO.

NCT ID: NCT05310422 Completed - Dry Eye Disease Clinical Trials

Safety Study of Tivanisiran to Treat Dry Eye

FYDES
Start date: March 24, 2022
Phase: Phase 3
Study type: Interventional

This study will examine the safety of tivanisiran sodium eye drops versus vehicle when dosed once daily for 1 year in subjects with signs and symptoms of dry eye disease (DED).

NCT ID: NCT05294328 Completed - Presbyopia Clinical Trials

Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

Start date: May 5, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.